Swiss biopharmaceutical company launched new clinical trials website

| |
0
79

Debiopharm International SA, part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, announced today the launch of its new clinical trials website.

The website provides patients and their caregivers with helpful information on Debiopharm’s clinical trials and studies. It also offers accessible information about the clinical trial process in general.

Debiopharm’s main therapeutic areas are oncology and infectious diseases. The company is currently conducting trials in multiple indications like Ovarian cancer, Head & Neck cancer and Non-Hodgkin Lymphoma. Additional studies are running in patients with Advanced Solid Malignancies as well. The website contains useful information for each clinical trial such as a short description of the trial process and its purpose, main inclusion criteria, as well as a map locating the study sites (in accordance with the information contained in the EU Clinical Trials Register and the clinicaltrials.gov website).

“This website is intended to be a helpful tool for patients and their families”, explains Christian Aeschlimann, Director of Clinical Operations at Debiopharm International SA. “They can find accessible information related to our clinical trials and treatment options. The website also allows users to share links of patient associations”.

Part of Debiopharm Group – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates.

SOURCE: debiopharm
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.
Isaltis Banner